Commitments and Contingencies (Details) (USD $)
|
9 Months Ended | 12 Months Ended |
---|---|---|
Sep. 30, 2013
|
Dec. 31, 2012
|
|
Abbott Biotherapeutics Corp [Member] | Phase I Clinical Trial of a licensed product [Member]
|
||
Summary of milestone payment | ||
Milestones payments | $ 750,000 | $ 750,000 |
Abbott Biotherapeutics Corp [Member] | Phase II Clinical Trial of a licensed product [Member]
|
||
Summary of milestone payment | ||
Milestones payments | 750,000 | 750,000 |
Abbott Biotherapeutics Corp [Member] | Phase III Clinical Trial of a licensed product [Member]
|
||
Summary of milestone payment | ||
Milestones payments | 1,500,000 | 1,500,000 |
Abbott Biotherapeutics Corp [Member] | Biological License Application filing with U.S. FDA [Member]
|
||
Summary of milestone payment | ||
Milestones payments | 1,750,000 | 1,750,000 |
Abbott Biotherapeutics Corp [Member] | First Commercial Sale [Member]
|
||
Summary of milestone payment | ||
Milestones payments | 1,500,000 | 1,500,000 |
Abbott Biotherapeutics Corp [Member] | After First Net Sales [Member]
|
||
Summary of milestone payment | ||
Milestones payments | 1,500,000 | 1,500,000 |
Memorial Sloan Kettering Cancer Center [Member] | New Drug Application [Member]
|
||
Summary of milestone payment | ||
Milestones payments | 750,000 | 750,000 |
Memorial Sloan Kettering Cancer Center [Member] | Receipt of Regulatory Approval From U.S. FDA [Member]
|
||
Summary of milestone payment | ||
Milestones payments | $ 1,750,000 | $ 1,750,000 |